肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗或仑伐替尼一线治疗后的序贯治疗
这项回顾性概念验证研究纳入1381例一线治疗后进展的肝细胞癌患者,比较不同二线治疗。一线仑伐替尼917例,阿替利珠单抗联合贝伐珠单抗464例。49.6%的患者接受了二线治疗,一线两种方案间总生存无统计学差异。
要点
- 49.6%的一线进展患者接受了二线治疗。
- 一线仑伐替尼后进展者,二线TACE总生存优于索拉非尼(24.7 vs 15.8个月,P<0.01,HR=0.64)。
- 一线阿替利珠单抗联合贝伐珠单抗后进展者,二线仑伐替尼总生存优于索拉非尼(17.0 vs 14.2个月,P=0.01,HR=0.45)。
核心结论
- 约半数接受一线仑伐替尼或阿替利珠单抗联合贝伐珠单抗治疗的患者接受了二线治疗。
- 数据提示,对阿替利珠单抗联合贝伐珠单抗进展的患者,能达到最长生存的系统治疗是仑伐替尼;对仑伐替尼进展的患者,能达到最长生存的系统治疗是免疫治疗。
研究设计与样本
- 回顾性概念验证研究,共纳入1381例一线治疗后进展的肝细胞癌患者。
- 917例接受仑伐替尼一线治疗,464例接受阿替利珠单抗联合贝伐珠单抗一线治疗。
主要发现
- 49.6%的进展患者接受了二线治疗;一线仑伐替尼与阿替利珠单抗联合贝伐珠单抗两组总生存无统计学差异(20.6个月 vs 15.7个月,p=0.12,HR=0.80)。
- 一线仑伐替尼后,二线治疗亚组间总生存无统计学差异(p=0.27;索拉非尼HR=1;免疫治疗HR=0.69;其他治疗HR=0.85)。
- 一线仑伐替尼后,接受TACE的患者总生存显著长于接受索拉非尼的患者(24.7个月 vs 15.8个月,p<0.01,HR=0.64)。
- 一线阿替利珠单抗联合贝伐珠单抗后,二线治疗亚组间总生存有统计学差异(p<0.01;索拉非尼HR=1;仑伐替尼HR=0.50;卡博替尼HR=1.29;其他治疗HR=0.54)。
- 一线阿替利珠单抗联合贝伐珠单抗后,接受仑伐替尼(17.0个月)和接受TACE(15.9个月)的患者总生存显著长于接受索拉非尼(14.2个月)的患者(分别为p=0.01,HR=0.45;p<0.05,HR=0.46)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab. MATERIALS AND METHODS: A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line. RESULTS: 49.6% of PD patients received a second-line therapy without any statistical difference in overall survival (OS) between lenvatinib (20.6months) and atezolizumab plus bevacizumab first-line (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After lenvatinib first-line, there wasn't any statistical difference between second-line therapy subgroups (p = 0.27; sorafenib HR: 1; immunotherapy HR: 0.69; other therapies HR: 0.85). Patients who underwent trans-arterial chemo-embolization (TACE) had a significative longer OS than patients who received sorafenib (24.7 versus 15.8months, p < 0.01; HR=0.64). After atezolizumab plus bevacizumab first-line, there was a statistical difference between second-line therapy subgroups (p < 0.01; sorafenib HR: 1; lenvatinib HR: 0.50; cabozantinib HR: 1.29; other therapies HR: 0.54). Patients who received lenvatinib (17.0months) and those who underwent TACE (15.9months) had a significative longer OS than patients treated with sorafenib (14.2months; respectively, p = 0.01; HR=0.45, and p < 0.05; HR=0.46). CONCLUSION: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy.
引用
- Persano M, Rimini M, Tada T, et al. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer. 2023. PMID: 37385069. doi:10.1016/j.ejca.2023.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。